PillRx only · Injection, Powder, For Solution · Intramuscular
Ceftriaxone
Ceftriaxone Sodium
6 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US13 NDCs
6 active makers
6 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 6 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$1.425
Latest avg · Jul 22, 2026
-3%
Since Dec 17, 2025
6
Active US suppliers
60%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
107K
Rx · 2026 Q1
129K
Units dispensed
-22%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it6 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| WG Critical Care, LLC | unknown | 5 | SUPPLYING |
| Hikma Pharmaceuticals USA Inc. | unknown | 4 | SUPPLYING |
| Civica, Inc. | unknown | 2 | SUPPLYING |
| Sagent Pharmaceuticals | unknown | 2 | SUPPLYING |
| Fresenius Kabi USA, LLC | unknown | 1 | SUPPLYING |
| Proficient Rx LP | unknown | 1 | SUPPLYING |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.